Critical appraisal of omega-3 fatty acids in attention-deficit/hyperactivity disorder treatment

Anja Königs
Amanda J Kiliaan

Department of Anatomy, Donders Institute for Brain, Cognition & Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands

Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder. The classical treatment of ADHD where stimulant medication is used has revealed severe side effects and intolerance. Consequently, the demand to search for alternative treatment has increased rapidly. When comparing levels of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) in ADHD patients with those in age-matching controls, lower levels are found in ADHD patients’ blood. ω-3 PUFAs are essential nutrients and necessary for a proper brain function and development. Additionally, there are strong indications that ω-3 PUFA supplements could have beneficial effects on ADHD. However, the results of ω-3 PUFA supplementation studies show a high variability. Therefore, we reviewed recent studies published between 2000 and 2015 to identify effective treatment combinations, the quality of design, and safety and tolerability of ω-3-containing food supplements. We searched the databases MEDLINE, PubMed, and Web of Science with keywords such as “ADHD” and “ω-3/ω-6 PUFA” and identified 25 studies that met the inclusion and exclusion criteria. The results of these ω-3 PUFA studies are contradictory but, overall, show evidence for a successful treatment of ADHD symptoms. Tolerability of the given supplements was high, and only mild side effects were reported. In conclusion, there is evidence that a ω-3 PUFA treatment has a positive effect on ADHD. It should be added that treatment could be more effective in patients with mild forms of ADHD. Moreover, the dosage of stimulant medication could be reduced when used in combination with ω-3 PUFA supplements. Further studies are necessary to investigate underlying mechanisms that can lead to a reduction of ADHD symptoms due to ω-3 PUFA treatments and also to determine the optimal concentrations of ω-3 PUFAs, whether used as single treatment or in combination with other medication.

Keywords: ADHD, ω-3 fatty acids, treatment, DHA, EPA

Introduction to the emerging use of omega-3 in attention-deficit/hyperactivity disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder, which has its onset in childhood but can also persist until adulthood.1 The overall pooled prevalence of ADHD in the world is 7.2% but differs between sex and age.2-4 In general, prevalence of ADHD is higher in males than in females and is most common in school-aged children. On the basis of criteria stated in the Diagnostic and Statistical Manual of Mental Disorders (DSM), ADHD patients can be divided into three groups: mainly inattentive, mainly hyperactive/impulsive, or a combination of both.1 The diagnosis is based on a number of age-dependent symptoms of inattention and/or hyperactivity/impulsivity that should occur for a period of at least 6 months. These symptoms often lead to severe problems in social behavior as well as in peer relationships. For ADHD patients, social life in a family environment and at school/work is therefore difficult.
Furthermore, ADHD is often accompanied with learning difficulties and mood and behavior disorders. Problems in social life are the main reason for ADHD treatment.

One of the most commonly used treatments for ADHD is the stimulant drug called methylphenidate. Due to side effects and unknown long-term effects, however, there are concerns about the use of methylphenidate. These concerns are the main reason for families to postpone methylphenidate treatment for months to years after a confirmed diagnosis of ADHD by a physician. The most important reason for families to start using methylphenidate as treatment for ADHD is the ultimate urge to solve problems at school, work, and home. This kind of stimulant medication is only treating symptoms however, and not the cause. This means that the drug is only effective for a couple of hours after intake (half-life time of intermediate-release methylphenidate is 2–4 hours) but will not change the situation over the long term. Studies have shown that stimulant drugs provoke mild side effects in most patients but also cause severe side effects, such as decreased appetite, insomnia, and headaches. These general concerns and side effects of the stimulant treatment clearly accentuate the need to search for alternative and less harmful treatments for ADHD. The best known alternative treatment is supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFAs).

It is interesting to use ω-3 PUFAs as treatment for ADHD since ADHD patients in general show a lack of ω-3 PUFAs. To understand the function of ω-3 PUFAs, the family of ω-6 PUFAs also need to be considered. The precursors of both ω-3 and ω-6 families are essential nutrients, which means that they cannot be produced by the body itself and should be obtained via dietary intake. In addition to the reliance on intake of essential PUFAs, processing of the precursors is inefficient in humans. During the Paleolithic period, the diet provided sufficient ω-3 PUFAs due to the high intake of fish. The ratio of ω-3 to ω-6 PUFAs was therefore high. In the western diet, the ratio is low due to an increase in ω-6 PUFAs and decrease in ω-3 PUFAs. Furthermore, ADHD is multifactorial and depends on genetic background on the one hand, and, for a large part on environmental factors on the other hand. Reduced ω-3 PUFAs levels in ADHD could be an interesting additional environmental factor because these deficiencies clearly have the greatest impact during the development of the central nervous system. This is also the time of onset of ADHD. This leads to the question whether a food supplement containing ω-3 PUFAs can serve as an alternative treatment for ADHD, taking into consideration that there are less side effects, a higher efficiency and less concerns about the impact on health. The purpose of this article is to critically review recent literature on ω-3 PUFAs treatment for ADHD, to determine 1) effective treatment combinations, 2) the quality of design of the clinical trials, and 3) the safety and tolerability of the food supplements.

**Rationale for ω-3 in ADHD**

To clarify the hypothesis that supplements containing ω-3 PUFAs could be used as effective ADHD treatment, the role of ω-3 PUFAs in the healthy brain in comparison with the brain of an ADHD patient needs to be discussed. When precursors of ω-3 and ω-6 long chain PUFAs (LCPUFAs) enter the body, they enter the same enzyme pathway. The precursor ω-linolenic acid (ALA) belongs to the group of ω-3 PUFAs and can be found in flax and in small amounts in soybeans, canola oil, and green leafy vegetables. The precursor can be converted into docosahexaenoic acid (DHA), which forms an important part in the production of phospholipids in neuronal membranes in the brain. DHA is responsible for fluidity and permeability of the neuronal membrane. High concentrations are found particularly in synapses, which makes DHA necessary for the function of neurons. An important intermediate is eicosapentaenoic acid (EPA), which is responsible for the production of eicosanoids. These eicosanoids can function as anti-inflammation signaling molecules. High concentrations of DHA and EPA are found in fish and fish oil.

Eicosanoids are also responsible for the regulation of the interaction of the ω-3 and ω-6 PUFA pathways. In addition to eicosanoids, the ratio between ω-3 and ω-6 PUFAs is also responsible for the regulation of both the pathways. A high intake of ω-6 PUFAs may inhibit the production of ω-3 PUFAs from its precursor and benefit processing of ω-6 PUFAs. The ω-6 PUFA precursor is linoleic acid (LA) and is transformed into arachidonic acid (AA) as an important intermediate. In addition to EPA, AA produces anti-inflammatory eicosanoids, which can also be found in reasonable amounts in neuronal membranes. The final product is docosapentaenoic acid (DPA), which has inflammatory effects.

Several arguments why ω-3 PUFAs may serve as good candidates for the treatment of ADHD can be found in literature. These arguments are based on the biochemical and physiological functions of ω-3 PUFAs. First, membranes of neurons contain high amounts of ω-3 and ω-6 PUFAs, especially DHA and AA, for proper neuronal function. The amount of ω-3 and ω-6 PUFAs affects the fluidity of the membrane, which could affect neurotransmission,
permeability, as well as structure and function of membrane-bound proteins. In blood and plasma of ADHD patients, the level of ω-3 PUFAs is lower than in age-matching controls. These lower levels can be found in children, adolescent, and adults.10–13 Postmortem measurements of the cortex showed that DHA concentration in a healthy brain increases until the age of 18 years.19 Furthermore, ω-3 PUFAs have an important function in brain development.20–23 This could explain why ω-3 PUFA deficiency during development has a wide impact on the function and development of the brain.

The second argument concerns the ratio of ω-3/ω-6 PUFAs in blood and plasma cells, which is lower in patients with ADHD. The relatively higher amount of ω-6 PUFAs may increase neuroinflammation. Since ADHD patients and controls consume similar amounts of ω-3 and ω-6 PUFAs, it is likely to presume that there are other causes for this change in ratio.10,13 One possible cause could be that processing of PUFAs is less effective in patients with ADHD.13 Common signs of essential fatty acid deficiency in ADHD patients are skin rashes and increased thirst.10 It is presumed that these symptoms are due to a deficiency in ω-6 PUFAs.24 In any case, it should be added that there is no competition between ω-3 and ω-6 PUFAs during uptake but only at processing level.25 This offers the opportunity to increase the amount of ω-3 PUFAs through higher dietary intake.

Search methodology

The following databases were searched between January 2000 and March 2016: MEDLINE, PubMed, and Web of Science. For this search, keywords such as Attention Deficit Hyperactivity Disorder (ADHD), ω-3 and ω-6 (long chain) polyunsaturated fatty acids (LCPUFAs), DHA, EPA, γ-linolenic acid (GLA), ALA, and fish oil were used. Other relevant information was also searched in references of reviews, studies, and meta-analyses. Inclusion criteria for trials were 1) a treatment with ω-3 PUFAs or in combination with ω-6 PUFAs, 2) a study design of open-labeled studies excluding a placebo group or double-blind studies including a placebo group, and 3) a diagnosis or suspicion of ADHD. Studies where ADHD was accompanied by the presence of a comorbidity were also included. As additional treatment, antioxidants such as vitamin E and carriers such as phospholipids, which improve the availability of PUFAs for the body, were included as well. Trials related to other deficiencies in combination with ω-3 PUFA deficiency such as zinc are excluded. Titles and abstracts of identified articles were controlled for inclusion and exclusion criteria. A flow diagram of the study selection is provided in Figure 1.

Results

In several studies, it has been indicated that a supplementation of ω-3 PUFAs has a beneficial effect on ADHD symptoms.26–30 However, results of these studies show a high variability and inconsistency about its effect on ADHD. In this review, only studies that were published between 2000 and 2015 are included. First, general information about all selected trials is provided followed by separate discussion on the results of each trial. These studies are divided into open-labeled trials without the presence of a placebo group (Table 1) and double-blind trials with the presence of a placebo group (Table 2).

The subjects who participated in these trials were mostly school-aged children from 6 to 13 years old. In fact, the total age range was 3.5–18 years. The predominant sex is male which is in accordance with the prevalence of ADHD in the population. In most cases, physicians officially diagnosed these children with ADHD in accordance with DSM-IV criteria.31–33 An alternative method used for the diagnosis of ADHD was via the criteria set in the Conners ADHD Index or Conners Rating Scale; scores higher than the 90th percentile in the parent-rated were used.28,29,34,35 Some studies also included children who had not been officially diagnosed with ADHD but who showed signs similar to children with ADHD.11,27–29,36–38

When taking comorbidity into account, it is evident that there are many common comorbid conditions associated with ADHD, which makes a homogeneous subject group difficult. In most studies, children with comorbidities of severe disorders were excluded. Examples of these disorders are neurological disorders and diseases such as epilepsy, mental retardation, autism spectrum disorder, mental insufficiency, encephalic malformations, including mechanical damage like a head injury leading to temporary loss of consciousness. Milder comorbidities such as
**Table 1 Clinical trials with fatty acid supplementation: open-labeled trials without a placebo group**

<table>
<thead>
<tr>
<th>References</th>
<th>Diagnosis</th>
<th>Age range, n (m, f)</th>
<th>Treatment in mg/d</th>
<th>Stimulant drug</th>
<th>Duration (weeks)</th>
<th>Measurements</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshi et al.</td>
<td>ADHD (DSM-IV)</td>
<td>Mean: 7.5/8, 60 (44, 16)</td>
<td>400 ALA, 50 vit. C</td>
<td>No</td>
<td>12</td>
<td>DSM-IV (P), blood FA pattern</td>
<td>Improvement in DSM-IV scores, increased EPA and DHA in RBC, decreased AA</td>
</tr>
<tr>
<td>Germano et al.</td>
<td>ADHD suspected by physician</td>
<td>3.5–16, 52 (90%, 10%)</td>
<td>2,202 DHA, 4,149 EPA, 461 α-ω, 1,137 other FA</td>
<td>No</td>
<td>8</td>
<td>ASQ-P/T, blood FA pattern</td>
<td>Improvement in inattention, hyperactivity, α-3 FA → lower ω-6/3 ratio</td>
</tr>
<tr>
<td>Sorgi et al.</td>
<td>ADHD (DSM-IV)</td>
<td>8–16, 9 (6, 3)</td>
<td>5,400 DHA, 10,800 EPA</td>
<td>3 no, 6 yes</td>
<td>8</td>
<td>ADHD SC-4 (I), CGI-S (I), ASQ-P, blood FA pattern</td>
<td>Improvement in ADHD SC-4 score, increase of EPA/DHA in PPL, correlation between CGI-S and AA/EPA ratio</td>
</tr>
<tr>
<td>Huss et al.</td>
<td>ADHD symptoms, no severity cutoffs or obligated diagnosis</td>
<td>5–12, 697 (71.5%, 28.5%)</td>
<td>40 DHA, 400 EPA, 60 GLA, 80 Mg</td>
<td>690 no, 9 yes</td>
<td>12</td>
<td>SNAP-IV (P), SDQ (P), sleep quality (P)</td>
<td>Reduction of hyperactivity/impulsivity, emotional and behavioral problems, less sleep problems</td>
</tr>
<tr>
<td>Barragán et al.</td>
<td>ADHD (DSM-IV)</td>
<td>6–12, 69 (33%, 67%)</td>
<td>174 DHA, 558 EPA, 60 GLA</td>
<td>30 no, 60 yes</td>
<td>36</td>
<td>ADHA RS (P), CGI-S (L)</td>
<td>Improvement for total ADHD/ hyperactivity–impulsivity for all groups</td>
</tr>
</tbody>
</table>

**Notes:** `n` is the number of subjects (treatment and control group) who finished the study. 'No information about whole group that finished the study, based on information about the treatment group. 'No information about the amount of males and females who have finished the study, percentage calculated on basis of the start population.' Treatment depends on the body weight of the participants, amount is calculated with the mean weight of 33.97 kg of the participants.

**Abbreviations:** AA, arachidonic acid; ADHD, attention-deficit/hyperactivity disorder; ADHD RS, ADHD Rating Scale; ADHD SC-4, ADHD Symptom Checklist-4; ALA, α-linolenic acid; ASQ-P, Conners’ Abbreviated Symptom Questionnaires (parent version); CGI-S, Clinical Global Impression of Severity of Illness; d, day; DHA, docosahexaenoic acid; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; EPA, eicosapentaenoic acid; f, female; FA, fatty acid; GLA, γ-linolenic acid; l, assessment is performed by investigator; m, male; P, questionnaire is rated by parents; PPL, plasmatic phospholipids; RBC, red blood cell; SDQ, Strengths and Difficulties Questionnaire; SNAP-IV, Swanson, Nolan, and Pelham IV; T, questionnaire is rated by a teacher; vit. vitamin.

The results of these studies showed improvement in ADHD symptoms in behavioral questionnaires, which were rated by parents and/or teachers and/or investigator. In addition, a positive effect in the blood fatty acid profile was found in the study of Barragan et al. In the comparison of PUFA's, a stimulating treatment was evaluated. Three studies were performed with the combination of both. This is a valuable information for scientists involved in designing less harmful treatments for ADHD. It should be noted that there were variations in diet used in these studies. A combination of DHA and EPA was used. In all the studies, DHA content was lower than that of EPA.
<table>
<thead>
<tr>
<th>References</th>
<th>Diagnosis</th>
<th>Age range, n (m, f)</th>
<th>Treatment in mg/d</th>
<th>Stimulant drug</th>
<th>Duration (weeks)</th>
<th>Measurements</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment based on ω-3 LCPUFAs only</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Voigt et al[11]</td>
<td>ADHD (DSM-IV)</td>
<td>6–12, 54 (42, 12)</td>
<td>345 DHA</td>
<td>Yes</td>
<td>16</td>
<td>TOVA (l), CCT (l), CBCL (P), CPRS, PPL FA patterns</td>
<td>No effect on ADHD symptoms, significant higher content of DHA in PPL</td>
</tr>
<tr>
<td>Hirayama et al[27,28]</td>
<td>ADHD (DSM-IV/symptoms)</td>
<td>6–12, 40 (32, 8)</td>
<td>514 DHA, 100 EPA</td>
<td>34 no, 6 yes</td>
<td>8</td>
<td>DSM-IV (P, T) criteria, different cognitive tests</td>
<td>No effect on ADHD symptoms, recalculation: improvement in hostility by parents rating and physical aggression by teachers rating Improvement in ASQ-P, decrease in inflammation and oxidative stress Improvement in CBCL in ADHD group and controls with active treatment, increased DHA levels in PL</td>
</tr>
<tr>
<td>Hariri et al[44]</td>
<td>ADHD (ASQ-P above 14)</td>
<td>6–11, 103 (67, 36)</td>
<td>195 DHA, 635 EPA, 100 other ω-3 FA</td>
<td>Yes</td>
<td>8</td>
<td>ASQ-P, blood FA pattern, oxidative stress, inflammation Cheek PL FA pattern, EFAQ (l), CBCL (P), SWAN (P), TRF, IMRI Go/NoGo-task, DLCQ, DA turnover in urine sample</td>
<td>Improvement in ASQ-P, decrease in inflammation and oxidative stress Improvement in CBCL in ADHD group and controls with active treatment, increased DHA levels in PL</td>
</tr>
<tr>
<td>Bos et al[30]</td>
<td>ADHD (DSM-IV)</td>
<td>8–14, 76 (76, 0)</td>
<td>650 DHA, 650 EPA</td>
<td>95% yes, 5% no</td>
<td>16</td>
<td>Cheek PL FA pattern, eFAQ (i), CBCL (P), SwAN (P), TRF, fMRI Go/NoGo-task, DLCQ, DA turnover in urine sample</td>
<td>Improvement in CBCL in ADHD group and controls with active treatment, increased DHA levels in PL</td>
</tr>
<tr>
<td><strong>Trials with both ω-3 LCPUFAs and vitamin E</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gustafsson et al[32]</td>
<td>ADHD (DSM-IV)</td>
<td>7–12, 92 (74, 18)</td>
<td>2.7 DHA, 500 EPA, 10 vit E</td>
<td>No</td>
<td>15</td>
<td>CPRS, CTRS, FA pattern of RBC and PPL</td>
<td>No general effects, improvement in CTRS in later defined subgroups in oppositional behavior and hyperactivity/impulsivity, increased EPA and decreased ω-6 in PL</td>
</tr>
<tr>
<td>Milte et al[35]</td>
<td>ADHD diagnosis (50%) or CPRS &gt;90th percentile (50%)</td>
<td>7–12, 87 (69, 18)</td>
<td>10 vit E +108 DHA, 1,109 EPA/1,032 DHA, 264 EPA</td>
<td>No</td>
<td>16</td>
<td>WIAT III (l), CPRS, WSCI III (l), cognitive assessment (l), RBC FA pattern</td>
<td>No general effect on ADHD symptoms, correlation between improvement in PUFA ratio and word reading, parent-rated oppositional behavior and anxiety/shyness, stronger in subtype with learning difficulties</td>
</tr>
<tr>
<td>Widenhorn-Müller et al[47]</td>
<td>ADHD (DSM-IV)</td>
<td>6–12, 95 (74, 21)</td>
<td>120 DHA, 600 EPA, 15 vit E</td>
<td>No</td>
<td>16</td>
<td>DISYPS-II (T, P), CBCL (P), TRF, HAWIK-IV, KITAP/TAP, blood FA pattern</td>
<td>No effects on ADHD symptoms, increased working memory function, increased DHA/EPA in RBC</td>
</tr>
<tr>
<td>Milte et al[34]</td>
<td>ADHD (official diagnosis, CPRS &gt;90th percentile)</td>
<td>6–13, 87 (67, 20)</td>
<td>10 vit E +108 DHA, 1,109 EPA/1,032 DHA, 264 EPA</td>
<td>No</td>
<td>12</td>
<td>WIAT III (l), CPRS, WSCI III (l), TEA-CH, RBC FA pattern, cognitive assessment</td>
<td>No effects on ADHD symptoms, correlation between PUFA ratio in RBC and behavior/literacy/attention</td>
</tr>
<tr>
<td><strong>Trials with ω-3/6 PUFAs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richardson et al[36]</td>
<td>ADHD symptoms (parent rating, clinical impression)</td>
<td>8–12, 29 (25, 4)</td>
<td>480 DHA, 180 EPA, 3 vit E, 864 LA, 42 AA, 8 thyme oil</td>
<td>No</td>
<td>12</td>
<td>CPRS</td>
<td>Improvement in 7 of 14 subscales of ADHD symptoms</td>
</tr>
<tr>
<td>Stevens et al[35]</td>
<td>ADHD (official diagnosis), thirst/skin symptoms</td>
<td>6–13, 33 (87%, 13%)</td>
<td>480 DHA, 80 EPA, 40 AA, 96 GLA, vit E acetate</td>
<td>Yes</td>
<td>16</td>
<td>CPT, WJ-R, skin/thirst questionnaire, ASQ-PIT, DBD (P, T), PPL &amp; RBC FA patterns</td>
<td>No effect on ADHD symptoms, improvement of ω-3 and ω-6 PUFA level in PPL &amp; RBC</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>References</th>
<th>Diagnosis</th>
<th>Age range, n (m, f)</th>
<th>Treatment in mg/d</th>
<th>Stimulant drug</th>
<th>Duration (weeks)</th>
<th>Measurements</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richardson et al[27]</td>
<td>ADHD symptoms (no official diagnosis)</td>
<td>5–12, 110 (67%, 33%)</td>
<td>174 DHA, 558 EPA, 60 GLA, 9.6 vit E</td>
<td>No</td>
<td>12</td>
<td>Movement ABC, WORD, CTRS</td>
<td>Increased literacy/CTRS</td>
</tr>
<tr>
<td>Sinn et al[28]</td>
<td>ADHD (no official diagnosis, ≥2SD on Conners ADHD index)</td>
<td>7–12, 104 (77, 27)</td>
<td>174 DHA, 558 EPA, 60 GLA, 10.8 vit E</td>
<td>No</td>
<td>15</td>
<td>CPRS, CTRS, cognitive measurements</td>
<td>Improvement in nine of 14 subscales of CPRS</td>
</tr>
<tr>
<td>Sinn et al[29]</td>
<td>ADHD (no official diagnosis, ≥2SD on Conners ADHD index)</td>
<td>7–12, 129 (96, 33)</td>
<td>174 DHA, 558 EPA, 60 GLA, 10.8 vit E</td>
<td>No</td>
<td>15</td>
<td>CPRS, cognitive tests</td>
<td>Improvement in switch and control of attention, vocabulary, CPRS</td>
</tr>
<tr>
<td>Johnson et al[30]</td>
<td>ADHD (DSM-IV)</td>
<td>8–18, 64 (54, 10)</td>
<td>174 DHA, 558 EPA, 60 GLA, 10.8 vit E</td>
<td>No</td>
<td>12</td>
<td>CGI-S (I), ADHD RS (-I, -IV) (I)</td>
<td>In general negative, inattentive subtype (26%) more than 25% improvement in CGI, ADHD-RS (-I, -IV) (all male) Reduced behavioral and learning difficulties after 6 months, inattentive subgroup already after 3 months</td>
</tr>
<tr>
<td>Perera et al[31]</td>
<td>ADHD (DSM-IV)</td>
<td>6–12, 94 (69, 25)</td>
<td>≥3 593, ≥6 361.5</td>
<td>Yes</td>
<td>24</td>
<td>Parent-rated ADHD symptoms/learning difficulties, nonverbal intelligence (I), sociodemography</td>
<td></td>
</tr>
<tr>
<td>Vaisman et al[32]</td>
<td>ADHD (diagnosis by clinical psychiatrist)</td>
<td>8–13, 60 (45, 15)</td>
<td>≤95 DHA, ≤155 EPA +550 other FA or 468 PL &amp; 329 other FA</td>
<td>No</td>
<td>12</td>
<td>TOVA (I), ASQ-P, PPL and RBC FA patterns</td>
<td>Improvement in TOVA with PL FA patterns</td>
</tr>
<tr>
<td>Belanger et al[33]</td>
<td>ADHD (DSM-IV)</td>
<td>6–11, 26 (18, 8)</td>
<td>200–400 DHA, 500–1,000 EPA, 0.19–0.56 vit E, 25–75 PL</td>
<td>No</td>
<td>8</td>
<td>SWAN (T, P), CPRS, CTRS, CPT (I), impulsivity measurement, blood FA patterns</td>
<td>No effects on ADHD symptoms, improvement in CPRS in treatment and placebo</td>
</tr>
<tr>
<td>Manoer et al[34]</td>
<td>ADHD (DSM-IV/ADHD RS-IV SD ≥1.5/CGR-I ≥4)</td>
<td>6–13, 147 (104, 43)</td>
<td>40 DHA, 80 EPA, 300 PS</td>
<td>No</td>
<td>15</td>
<td>CPRS, CTRS, SDQ (P, T), CHQ</td>
<td>No general effects, improvement in 1 subscale of CPRS and CHQ</td>
</tr>
<tr>
<td>Trials with ω-3 LCPUFAs and phospholipids</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raz et al[35]</td>
<td>ADHD (diagnosis by physician)</td>
<td>7–13, 63 (38, 25)</td>
<td>120 ALA, 480 LA, 190 mineral oil, 10 vit E</td>
<td>No</td>
<td>7</td>
<td>EFA deficiency questionnaire (P), ASQ-P/IT, DSM-IV (P), TOVA (I)</td>
<td>No effect on ADHD symptoms</td>
</tr>
<tr>
<td>Dubnov-Raz et al[36]</td>
<td>ADHD (DSM-IV)</td>
<td>6–16, 17 (10, 7)</td>
<td>1,000 ALA, 320 LA, 400 oleic acid, 120 palmitic acid, 40 stearic acid</td>
<td>No</td>
<td>8</td>
<td>CPRS, CTRS, MOXO-CPT (I), DSM questionnaire (P, T)</td>
<td>No effect on ADHD symptoms</td>
</tr>
</tbody>
</table>

Notes: n is the number of subjects (treatment and control group) who have finished the study. *No information about the amount of males and females who have finished the study, percentage calculated on basis of the start population.

Abbreviations: AA, arachidonic acid; ADHD, attention-deficit/hyperactivity disorder; ADHD RS-IV, ADHD Rating Scale IV; ALA, α-linolenic acid; ASQ-P/IT, Conners’ Abbreviated Symptoms Questionnaires (parent/teacher version); CBCL, Child Behavior Checklist; CCT, Children’s Color Trails; CGI-S, Clinical Global Impression of Severity of Illness; CHQ, Child Health Questionnaire; CPRS, Conners’ Parent Rating Scale; CPT, Conners’ Continuous Performance Test; CTRS, Conners’ Teacher Rating Scale; d, day; DA, dopamine; DBD, Disruptive Behavior Rating Scale; DHA, docosahexaenoic acid; DISYPS-II (parent/teacher), Diagnostik-System für psychische Störungen: parent/teacher questionnaire; DLCQ, Diet and Lifestyle Change Questionnaire; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; EFAQ, Essential Fatty Acids Questionnaire; EPA, eicosapentaenoic acid; f, female; FA, fatty acid; fMRI, functional magnetic resonance imaging; GLA, γ-linolenic acid; HAWIK-IV, Hamburg Wechsler Intelligence Scales for Children IV; I, assessment is performed by investigator; KITAP/TAP, Testbatterie zur Aufmerksamkeitsprüfung für Kinder/Testbatterie zur Aufmerksamkeitsprüfung, computerized test batteries for attention performance for children; LA, linoleic acid; LCPUFA, long-chain polyunsaturated fatty acid; m, male; Movement ABC, Movement Assessment Battery for Children; MOXO-CPT, MOXO-Computerized Continuous Performance Test; P, questionnaire is rated by parents; PL, phospholipids; PPL, plasmatic phospholipids; PS, phosphatidylserine; PUFA, polyunsaturated fatty acid; RBC, red blood cell; SD, standard deviation; SDQ, Strengths and Difficulties Questionnaire; T, questionnaire is rated by a teacher; TEA-CH: Test of Everyday Attention for Children; SWAN (teacher/parent), the strengths and weaknesses in ADHD and normal behaviors; TOVA, test of variables of attention; TRF, Teacher’s Report Form; vit, vitamin; WIAT III: Wechsler Individual Achievement Test iii; wJ-R: Woodcock-Johnson Psycho-Educational Battery-Revised; WORD, Wechsler Objective Reading Dimensions; WSCIII, Wechsler Scale of Children’s Intelligence.
In conclusion, single treatment with DHA alone does not show promising results. However in this study, all the participants were taking stimulant medication while assessing behavior. The stimulant medication was able to ameliorate behavioral symptoms thereby leaving little room for further improvement by DHA. On the other hand, a combination of DHA with EPA resulted in improvement of some ADHD symptoms. The results of Hirayama et al were not included in this conclusion because of the subject population that was used; the study comprised eight subjects (20%) of whom diagnosis of ADHD is arbitrary and not clear whether they could be diagnosed with ADHD, if rated by DSM-IV criteria. Furthermore, the treatment with stimulant drugs was inconsistent, and there was a high percentage of variable comorbidities, for example, subjects with Asperger’s syndrome, conduct disorder, learning disorder, or mood disorder were included. Moreover, the study was carried out in Japan where intake of ω-3 fatty acids is high due to a high average consumption of fish. In this study, baseline fatty acid levels in blood were neither analyzed nor compared with values of ADHD patients in other countries. The experiment was also underpowered due to its small sample size. An interesting aspect of this study was the treatment that was chosen; instead of providing subjects supplements with fish oil or other fatty acids, the supplements were put in fermented soybean milk, bread rolls, and steamed bread, primarily to mask the taste of fish oil. Another study where other food products were used concerns the study of Bos et al supplements or placebos were put in margarine.

Trials with both ω-3 LCPUFAs and vitamin E

In four trials, vitamin E was added to ω-3 LCPUFAs as a measure to protect against easy oxidization of LCPUFAs. In all these studies, a combination of 10–15 mg vitamin E with ω-3 LCPUFAs was given to children who did not take any stimulant treatment. In two studies, a food supplement with a low amount of DHA and a high amount of EPA (2.7 mg DHA +500 mg EPA/120 mg DHA +600 mg EPA) was used. In general, these studies failed to show positive effects. Based on the teachers rated Conners Rating Scale, only one study found improvement in one, later-defined subgroup as far as oppositional behavior and hyperactivity/impulsivity are concerned. Two other studies by Milte et al in 2012 and 2015 compared different ratios of DHA to EPA: 1:10 (108 mg DHA, 1,109 mg EPA) and 4:1 (1,032 mg DHA, 264 mg EPA). These studies also failed to show amelioration of ADHD symptoms. However, improved fatty acid profile in erythrocytes was correlated with

Results of double-blind placebo-controlled trials

An overview of the double-blind trials with placebo groups can be found in Table 2. These studies are classified in accordance with the different compositions used in the PUFA supplements. There is only limited information provided about the rationale for the used PUFA concentrations provided to the participants. Most studies used combinations that were already successfully tested in earlier trials. At the moment, there are no studies that performed dose response of ω-3 PUFAs treatment in ADHD. It is of importance that future studies will address this.

Treatment based on ω-3 LCPUFAs only

ω-3 LCPUFAs treatment was tested in four studies. In all these studies, the majority of children was treated with stimulant medication. The used type and amount of ω-3 PUFA differed between trials: In one study, only DHA (345 mg per day), in combination with a prescribed stimulant medication, was used. This study failed to show improvement in ADHD symptoms on the basis of measurements with regard to attention and impulsivity and parent-rated behavior.

Three other studies showed a significant improvement in some ADHD symptoms: Hirayama et al found improvement in parent-rated hostility and teacher-rated aggression using a treatment of 514 mg DHA and 100 mg EPA per day. Six subjects (15%) used stimulant medication besides the food supplement. A treatment with 195 mg DHA, 635 mg EPA, 100 mg other ω-3 FA in combination with stimulant medication led to improvement in scores on the parent-rated Conners’ Abbreviated Symptom Questionnaires, as well as a decrease in inflammation and oxidative stress. The study of Bos et al demonstrated improvement after treatment in both the ADHD group and the control group as based on the parent-rated Child Behavior Checklist. The treatment used consisted of 650 mg DHA and EPA.

In comparison with other studies, the dietary composition in the study of Sorgi et al and Germano et al is remarkable because of the use of high amounts of EPA and DHA. The supplement contained 5,400 mg DHA and 10,800 mg EPA/2,202 mg DHA and 4,149 mg EPA, while other studies used a maximum of 174 mg DHA and 558 mg EPA. In the remaining study, ALA was used instead of DHA and EPA, which is, in fact, a precursor of DHA and EPA. This is surprising because it is presumed that the processing of the precursors of ω-3/6 fatty acids in the human body is less effective.

ω-3 fatty acids as ADHD treatment
improvement in outcome measures. The 2012 study showed a correlation with improvement in word reading, parent-rated oppositional behavior, and anxiety/shyness. This correlation was even stronger in the subtype with learning difficulties. The study performed in 2015 revealed correlations with improvement in literacy, attention, and behavior. It has to be mentioned that there were inconsistencies in compliance in the study performed in 2012. The highest compliances were found in the treatment groups that also showed the largest improvement in blood fatty acid levels. There are some other limitations in this study: an official diagnosis of ADHD was lacking in 50% of the children included, and also children with comorbidities such as mood or conduct disorders were included.

From the four studies aforementioned, it can be suggested that the ratio between DHA and EPA is not the most important factor in the treatment against ADHD. This suggestion is supported by a study in which it has been shown that processing is, in fact, a vital step. This means that it is not the ratio, but, in fact, the amount of ω-3 PUFAs which is important. An addition of vitamin E, together with its antioxidant capacities, did not show any effect either. However, some changes in the fatty acid profile in the blood were correlated with improvement in outcome measurements.

**Trials with ω-3/6 PUFAs**

Seven trials included treatments containing both ω-3 and ω-6 LCPUFAs. In 2002, Richardson et al tested a supplement containing 480 mg DHA, 180 mg EPA, 864 mg LA, 42 mg AA, 3 mg vitamin E, and 8 mg thyme oil. This study reported an improvement in the parent-rated Conners Rating Scale. Subjects were children aged between 8 and 12 years. All had reading and writing problems and were suspected of having ADHD. However, ADHD had not been officially diagnosed and, thus, no stimulant medication had been prescribed. Another issue is the small sample size of 29 participants. In another study, a comparable treatment was used, but with different amounts: 480 mg DHA, 80 mg EPA, 96 mg GLA instead of the precursor LA, 40 mg AA, and vitamin E acetate. In this study, children were taking stimulant medication in combination with the food supplement. Except for an improvement in the ratio of ω-3/ω-6 fatty acids in erythrocytes and plasma phospholipids, no other effects were found. However, improvement in behavior was found in both placebo and treatment group. This suggests that these effects are not specific for the active treatment. Also in this study, the small sample size should be taken into account (N=33). In a third study, a high concentration of ω-3 LCPUFAs (593 mg) and a low amount of ω-6 LCPUFAs (361.5 mg) in combination with stimulant treatment were used. It was not specified which particular unsaturated fatty acids were used. After 6 months, a successful reduction in behavioral and learning problems was detected and a significant improvement was already apparent after 3 months of treatment in a subgroup of inattentive subjects. It should be noted that this subgroup was defined after the study had been completed.

In 2005, Richardson et al completed a study in which a low DHA and high EPA content with additional ω-6 PUFAs was used (174 mg DHA, 558 mg EPA, 60 mg GLA, and 9.6 mg vitamin E). During experiments, no stimulant medication was taken by any of the children. Almost the same combination of treatment had already been used in three other studies (174 mg DHA, 558 mg EPA, 60 mg GLA, and 10.8 mg vitamin E). When comparing these four studies in total, three out of four studies showed a general improvement in ADHD symptoms, such as literacy, and switch and control of attention. This was based on information from the Conners Rating Scales, completed by teachers and parents. The fourth study showed an improvement only in a subgroup of inattentive patients, measured by the ADHD Rating Scale and Clinical Global Impression of Severity of Illness.

In summary, a treatment with ω-3 fatty acid DHA and EPA in combination with ω-6 fatty acids GLA or LA and vitamin E seems to be effective in treating ADHD symptoms. The treatment with 174 mg DHA, 558 mg EPA, 60 mg GLA, 9.6 or 10.8 mg vitamin E was tested in four studies, which led to promising results. Three studies succeeded in showing improvement in ADHD symptoms. One of these studies and the study supplementing 593 mg ω-3 PUFAs and 361.5 mg ω-6 PUFAs reported more improvement in the inattentive subtype. However, these subgroups were defined after studies had been completed. In further research, it is recommendable to repeat the same treatment but define all of these different subtypes before starting the study and include all of these different subtypes in the investigation.

**Trials with ω-3 LCPUFAs and phospholipids**

Apart from ω-3 fatty acids, phospholipids were also included in three of the studies during treatment. It has been demonstrated in animal studies that phospholipids can function as carriers for LCPUFAs to increase the availability of the LCPUFAs for uptake in the body. Subjects using stimulant medication were excluded in all of these three studies. In the trial of Vaisman et al, one of the following combinations was used; either 95 mg DHA,
155 mg EPA, and 550 mg other saturated and unsaturated fatty acids or 468 mg phospholipids and 329 mg other fatty acids. When checked against the criteria set in the Test of Variables of Attention, only the treatment with additional phospholipids led to an increase in scores. In another study, the concentration of dietary components in the supplements used was determined based on the participant’s body weight. For example, children with a body weight between 26 and 35 kg were treated with 300 mg DHA, 750 mg EPA, 38 mg vitamin E, and 50 mg plasma phospholipids. In this particular study, the treatment failed to show any effect. However, when checked against the criteria set in the parent- and teacher-rated Conners Rating Scale, another unexpected improvement was found in the treatment group as well as the placebo group. A major criticism of this study is the small sample size (N=26). The study of Manor et al. used food supplements containing 40 mg DHA, 80 mg EPA, and 300 mg phosphatidylserine. Results did not show any effect, except for improvement in the restless/impulsive subscale rating of the Conners Rating Scale for parents and the parent impact-emotional subscale of the Child Health Questionnaire. One explanation could be the small number of participants (N=17).

In conclusion, there is little evidence that a combination of phospholipids and ω-3 FA can affect ADHD symptoms. As shown in the study of Manor et al., there is only little evidence as to whether this has an effect on treating ADHD. This study included behavioral ratings from teachers who were not trained to rate ADHD symptoms. These teachers had up to 42 children in a classroom, and some of these teachers were replaced during the period of study. More positive effects could possibly be found when improving the rating quality to be filled in by teachers. Further studies should be performed before drawing any other conclusions about the effect of ω-6 LCPUFAs in combination with phospholipids on ADHD symptoms.

Trials with ω-3/ω-6 LCPUFA precursors
Precursors of ω-3/ω-6 LCPUFAs were used in two studies. In the first study, a combination of 120 mg ALA, 480 mg LA in combination with 190 mg mineral oil and 10 mg vitamin E was used, but this combination failed to show any improvement in ADHD symptoms. The second study used a much higher amount of ALA (1,000 mg ALA including 320 mg LA, 400 mg oleic acid, 120 mg palmitic acid, and 40 mg stearic acid), but lacked any positive results as well. This supports the argument that intake of ω-3/ω-6 PUFA precursors has a lower efficiency than intake of ω-3/ω-6 LCPUFAs, probably due to the low processing efficiency of the precursors. Furthermore, there is evidence that ALA-rich diets reduce the conversion rate from ALA to EPA, while it increases the oxidation rate of ALA.  

General conclusion
The results of the studies described above are inconsistent. All trials without placebo group showed positive results. These results should be interpreted with care, however, because a placebo group is missing. The study of Barragán et al. had an interesting design in which effects of a food supplement were compared to effects of stimulant medication as well as the combination of both. It would be helpful to repeat this study in a double-blind design including the use of a placebo group in order to get more information about the possibility to reduce the amount of given stimulant medication.

Adding a placebo group and using a double-blind study design only led to positive results in few studies. There was little evidence that the single ω-3 LCPUFAs treatment had any effect on ADHD symptoms. Studies that had shown positive effects used very small number of participants (n=9) or had a high variability in ADHD diagnosis in combination with comorbidities. The study of Bos et al. demonstrated a positive effect both in the ADHD group and in the control group when using an active treatment of 650 mg DHA and EPA. This suggests that an improvement of behavior through additional ω-3 LCPUFAs is not ADHD-specific. Adding vitamin E to ω-3 LCPUFAs did not show any convincing results either. Only in one study, an improvement in the hyperactive and impulsive subgroup could be found. The division in subgroups was however exerted after finishing the study. In order to obtain more reliable results, this study should be repeated after a clear division of subtypes has been realized before the start of the study, thus resulting in getting more information about the effect of ω-3 treatment in combination with vitamin E in the hyperactive/impulsive subtype.

Treatment with a combination of ω-3 and ω-6 LCPUFAs showed much more promising results. Positive results on ADHD symptoms were found in five studies. In several studies, a treatment with 174 mg DHA, 558 mg EPA, 60 mg GLA, 9.6 or 10.8 mg vitamin E particularly showed promising results. In four of these studies, however, children without ADHD diagnosis were also included. The only study that used the same treatment in officially diagnosed ADHD patients did not show any effect. On the basis of two questionnaires, the only improvement could be detected in the inattentive subtype. On the whole, studies where a combination of ω-3 and phospholipids was used, showed negative results, except for the study of Manor et al. Even though the
last combination with ω-3 and ω-6 precursors failed to show any improvement during testing. This outcome reinforces the idea that the processing mechanism in the human body has a low efficiency for ω-3 and ω-6 precursors.¹⁴

Critical analysis of the study design

Sample size

A general discussion point is the underpowering of some of the studies due to small number of subjects, which makes it difficult to show any effect whatsoever.⁵⁸ In order to get sufficient statistical power, Bloch and Qawasmi⁵⁹ set up a meta-analysis in which they calculated a sample size of at least 330 participants. This is especially a problem in studies where a heterogenic patient population is used. Heterogeneity in patient groups is created by different subtypes of ADHD, different comorbidities, inconsistency in the treatment of ADHD with stimulant medication, and differences in age and sex.

Age and sex

The age of the participants ranged from 3.5 to 18 years. The majority of the children were school-aged between 6 and 13 years. This age range covers all ages where ADHD occurs the most. However, ADHD persist also until adulthood, and it would be useful to include also subjects >18 years in trials with ω-3-containing food supplements.

One should also carefully consider conclusions drawn about differences in sex because there are mostly more male than female participants included in the trials. A study with ω-3 PUFAs supplementation in rats showed that there are sex differences concerning hyperactivity and impulsive-ness symptoms; a clear improvement in hyperactivity and impulsiveness symptoms could be detected in male rats, whereas in females, there were no effects or oppositional effects instead.⁶⁰ The changes in male rats were associated with changes in the neurotransmitter turnover in the brain. Furthermore, the conversion efficiency of ALA into EPA and DHA seems to be higher in men than in women.⁶¹,⁶² This is in line with the higher prevalence of ADHD in men than in women. The study was performed with reproductive women and suggested a potential effect from estrogens on the conversion from ALA into DHA. These results suggest that it is more important for men to consume the intermediate EPA and final product DHA than their precursor ALA, due to the low efficiency of ALA processing. It was proven that a higher intake of ALA failed to show an increased amount of DHA in the erythrocytes membrane in men while there was a successful conversion to DHA.⁶² Another study suggested differences between women and men in processing speed and physiological needs.⁵ The influence of estrogen was also mentioned here.

Treatment

The composition and the amount of the different dietary lipid components in the supplements varied between the studies. This makes comparison of the results of different studies difficult. To determine effective treatment compositions, dose–response trials should also be performed in future studies. Furthermore, there is only limited information provided on which a certain composition was based. Often, treatment compositions from earlier studies were reused. In addition, the use of food supplements in participants on stimulant medication has to be considered: it is difficult to find the effects of supplements on top of the improvement due to stimulant medication. Also the baseline levels of ADHD symptoms can be biased because the stimulant medication already suppresses the symptoms of ADHD.

Study period

Trials usually lasted 8 or 12 weeks. In comparison with this, the 36-week study of Barragán et al.⁶⁶ was really long. The length of the studies should depend on the recovery time of the fatty acid profile both in the blood and in the brain. Evidence from a rat study in which DHA recovery was measured after DHA deficiency showed that the level of recovery in serum is 93% after 4 weeks and 106% after 8 weeks.⁶³ Brain recovery reached a lower percentage of merely 80% after 8 weeks. Additionally, it should be considered that blood fatty acid profiles may be not representative for brain fatty acid contents, especially not in subjects who are younger than 18 years.⁶⁴ Moreover, long-term effects should be tested in periods lasting much longer than 8 weeks. The study of Perera et al.⁶⁵ measured the effect of treatment after 3 and 6 months. In general, they found a reduction in behavioral and learning difficulties after 6 months. In the inattentive subtype, this was already visible after 3 months. This indicates that treatment effects could be seen much later than in 8 up to 12 months, a period of time that is used in most studies. Taking trial lengths together with the recovery time of fatty acid profiles into consideration suggests that trials should not be shorter than 8 weeks. A longer treatment is advisable, however, in order to find effects that can only be detected after a longer period of supplementation and that depend on the recovery of fatty acid profiles.

Assessment

In general, a low number of different measurements was used in the studies which, moreover, varied between the trials.
This makes comparisons between the studies difficult. In most cases, only two or three different questionnaires or tests were conducted to investigate ADHD symptoms. Some studies additionally measured the fatty acid profile in the blood which is also considered as appropriate estimation of the brain fatty acid content. However, there is evidence that under the age of 18, the blood fatty acid content is correlated to the brain fatty acid content only to a certain extent. Questionnaires often depended on ratings given by parents or teachers. A problem with the parents’ ratings is the comprehension of the questionnaires. When completing the Child Behavior Checklist, Widenhorn-Müller et al found that parents might have problems understanding the questions correctly. Parents were asked to rate and explain the children’s behavior. Ratings were given, but the description of behavior was often missing due to a possible lack of comprehension. This problem was solved in the study of Germano et al in which parents were trained to rate their child’s behavior. It should be considered that all questionnaires are subjective, consequently influencing the results. Another problem with teacher-rated questionnaires are factors such as holidays, the occurrence of big pupil groups, and only a small number of contact hours with the subject. In trials that were not blinded, prior knowledge of giving active treatment could influence the judgment of teachers, parents, and physicians alike. In conclusion, trials differed in many ways, which makes it difficult to make a comparison and to estimate the reliability of results. For future studies, homogeneous groups of subjects and a clear division between the subtypes are advisable.

Safety and tolerability

To provide an alternative to stimulant medication, it is necessary to consider the safety and tolerability of the ω-3 PUFA food supplements. Food supplements that have been described in this critical appraisal showed a good tolerability in general. Tolerability can be judged by the dropout rate and its reported side effects in relation to aversive events. In all these reviewed studies, only a few participants dropped out because of aversive events. Most common side effects during treatments with an ω-3 PUFA supplement were related to gastrointestinal discomfort, such as stomach ache, feeling sick, and diarrhoea. Nose bleeds were also reported, but far less frequent. One study investigated the safety of phosphatidylserine-containing supplements over a period of 30 weeks. During the first 15 weeks, double-blind and placebo-controlled trials were carried out followed by a 15-week open-labeled extension phase. During the first 15 weeks, a combination of 300 mg phosphatidylserine, 80 mg EPA, and 40 mg DHA was given. During the open-labeled phase, half of this amount was given. Results showed no effect on physical parameters and no differences between placebo groups and treatment groups. This study concluded that the tested treatment was well tolerated.

Tolerability of ω-3 LCPUFAs in ADHD patients has not been investigated in studies lasting longer than 36 weeks yet. In two studies, lasting 30 and 36 weeks each, a treatment of 174 mg DHA, 558 mg EPA, and 60 mg GLA and in one study 10.8 mg vitamin E was given. Gastrointestinal discomfort and incidental nose bleeds were side effects reported by only some subjects. Two other subjects indicated a loss of appetite. Similar side effects, also in rare cases, were found in another study with regard to behavioral problems in children between 8 and 16 years. During this study, a double-blind trial with 100 participants in total was carried out. These participants were divided into a placebo group and a treatment group. Treatment consisted of a combination of 300 mg DHA, 200 mg EPA, 400 mg ALA, and 100 mg DPA. It can be noted that different quantities of ω-3 LCPUFAs were given in the reviewed studies. Tolerability of the food supplements did not seem to be affected however. Moreover, the use of higher amounts of LCPUFAs such as 2,202 mg DHA, 4,149 mg EPA, 461 mg ω-6, and 1,137 mg other fatty acids or 5,400 mg DHA and 10,800 mg EPA were well tolerated by the participants. Side effects of a ω-3 LCPUFAs treatment, in comparison with treatment with methylphenidate, were analyzed in the study of Barragán et al. The most reported side effect was loss of appetite, which was found in 53% of participants taking the methylphenidate supplement but only in 27% of participants taking an additional food supplement.

When summarizing the tolerability of treatment, it can be concluded that there are no reports about severe side effects. The most frequently reported side effects were gastrointestinal discomfort and incidental nose bleeds but in comparison with methylphenidate much less side effects occur. Well-known side effects of a treatment with regard to a methylphenidate treatment are decreased appetite, insomnia, and headaches. This makes a treatment with ω-3 LCPUFAs all the more attractive, as a less harmful alternative for methylphenidate or any other stimulant medication.

Patient-focused perspective

The most important reason to treat ADHD are problems in daily life specifically in the family environment, at school, or at work. The most common treatment for ADHD is stimulant medication. However, this treatment has often been criticized because of its severe side effects. Examples are
insomnia and decreased appetite, which are more often found in younger and smaller children. In children with milder forms of ADHD, parents often decide not to give stimulant medication because the positive effects do not outweigh the side effects. An alternative with less harmful side effects is desirable for this group, particularly, resulting in making their daily life situations easier and to increase the quality of life. In order to reach this goal, treatments with food supplements containing ω-3 LCPUFAs could be a good solution. This critical appraisal of reviewed studies shows that there is a good basis for treatments with ω-3 LCPUFAs. Compliance rates with regard to these treatments were usually high. Most frequently reported problems are in comparison to stimulant medication. These were difficulties in swallowing capsules and a dislike of the fishy taste of the supplement, which led to a rejection of capsules in some cases. The studies of Hirayama et al and Bos et al showed a solution to these two difficulties; the fishy taste was masked as the supplement was put in soybean milk, bread rolls, and steamed bread or margarine, and the portions of which were given to patients at a daily basis. However, it is a questionable way of delivering PUFA as this way because it has to be considered that margarine could increase the risk of oxidations.

**Conclusion and place in therapy**

This review aimed to identify effective treatment compositions of ω-3 PUFA food supplements, its safety and tolerability, and the quality of design of the studies. Reviewed studies show inconsistent results. Therefore, clear convincing effects of LCPUFAs supplements to decrease ADHD symptoms are still lacking. The most promising results are found in trials where treatments combining ω-3 and ω-6 LCPUFAs were given. The tolerability of supplements was good, and only mild side effects such as gastrointestinal discomfort and very incidental bleeds were reported. The main issues of the study design are small sample sizes, high variability in study design, and exerted assessment methods. Future studies should include sufficient participants in double-blind and placebo-controlled trials. To make the results easier to compare, blood fatty acid measurements should be included to provide a more reliable assessment of ω-3 baseline levels and possible improvements.

Two particular patient groups could benefit from a possible treatment with ω-3 PUFA: First, LCPUFAs treatment could replace stimulant treatment for patients with milder forms of ADHD. In this patient group, side effects of stimulant medication outweigh the benefits. This leads to untreated cases of ADHD which, in turn, results in an increase in problems in daily life. The second group consists of patients who suffer both from severe ADHD and from side effects of the stimulant treatment. In this patient group, a combination of stimulant medication with ω-3 food supplements could reduce the given amount of stimulant medication, in order to reduce the suffering from side effects. Further studies are suggested to demonstrate the effects of food supplements with ω-3 LCPUFAs on ADHD symptoms.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


